Merck &Co Inc USA, which is one of the world's largest pharmaceutical companies, had been a marginal player in the R55,000 crore Indian drug market till early this year. However, the acquisition of Schering Plough's two operating companies in India — Fulford and Organon — has almost trebled Merck's India footprint through its domestic affiliate MSD Pharmaceu-ticals. KG Ananthakrishnan, MSD's new chief operating officer shares his vision for the company with HT...
How does the merger of the three companies help Merck as a whole?
Operationally, the three companies have merged. We did this because the three companies on their own have tremendous synergies. This has helped expand our product portfolio and size and increase our penetration into the market.
Does that mean that Fulford and Organon India cease to exist and only MSD remains?
The three companies continue to operate as before but under the umbrella MSD logo. There is no change in the way we work and for now there are no plans to change anything legally.
Which of the three firms is the largest in size and which is the one that is growing the most?
The three comapnies contribute equally to the company's bottom- and toplines and fortunately for us all of them are growing at a robust pace.
What is the company's roadmap, going forward?
We have a huge product lineup from our parent company in the US and we intend to bring them all gradually into India. You will see us getting very aggressive and the merger only helps our cause. Our thrust area will be vaccines because that is where scientific innovations are happening the most.